Interferon-Alpha-Neurotoxicity

干扰素-α-神经毒性

• 批准号: 8541199
• 负责人: WILLIAM R TYOR
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-10-01 至 2017-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8541199
• 关键词: A Mouse; Adverse effects; Animals; Anti-Retroviral Agents; Antibodies; Antiviral Agents; Behavioral; Blood - brain barrier anatomy; Brain; Brain Diseases; Combined Modality Therapy; Data; Disease; Dose; Encephalitis; Exhibits; Exposure to; Functional disorder; Genes; Goals; Grant; HIV; HIV Infections; HIV encephalitis; Histopathology; Human; IFNAR1 gene; Impaired cognition; In Vitro; Infection; Interferon Receptor; Interferon-alpha; Interferons; Lead; Length; Mediating; Memory; Mus; N-Methyl-D-Aspartate Receptors; N-Methylaspartate; Neuraxis; Neurocognitive; Neuronal Dysfunction; Neurons; Pathway interactions; Phosphorylation; Play; Radial; Rattus; Reactive Oxygen Species; Regimen; Research; Role; SCID Mice; STAT1 gene; Signal Pathway; Signal Transduction; Simulate; System; Testing; Therapeutic; Use Effectiveness; Viral Cancer; Viral Load result; Viral hepatitis; Water; alternative treatment; antiretroviral therapy; arm; base; cytokine; fetal; fighting; immunogenic; in vivo; insight; neurotoxic; neurotoxicity; neutralizing antibody; novel; prevent; public health relevance; receptor; stem

DESCRIPTION (provided by applicant): Interferon (IFN)a is an antiviral cytokine that has adverse effects on neuronal function. When IFNa is used as a treatment for diseases such as viral hepatitis and cancer, it can cause cognitive dysfunction if it is given in sufficient quantities and for prolonged periods. IFNa is elevated in the central nervous system (CNS) of a number of diseases associated with cognitive dysfunction, most prominently in HIV associated neurocognitive disorders (HAND). There is abundant data both in animal studies and in vitro demonstrating that IFNa is associated with neuronal dysfunction. IFNa is elevated in SCID mice with HIV encephalitis (HIVE) and is correlated with the degree of behavioral dysfunction exhibited during water radial arm maze (WRAM) testing. When HIVE mice are treated with neutralizing antibodies (NAb) to IFNa, behavioral abnormalities on WRAM testing and some aspects of HIVE histopathology are prevented or substantially reduced. To begin to understand the effects of IFNa on MAP2 expression and dendritic formation in neurons, an in vitro system using fetal rat neurons was used. These neuronal cultures reveal a dose dependent decrease in dendritic length and branching when exposed to IFNa. This effect is blocked by NAb to IFNa and partially ameliorated by NMDA antagonists. In this competitive renewal it is proposed that in vivo studies initiated during the previous grant (see above) will be extended by treating HIVE mice with a novel IFNa blocker, B18R (NormferonTM-alpha). This agent is more practical than NAb to IFNa for moving into human trials, primarily because it is less immunogenic, among other potential advantages. It appears likely that B18R crosses the blood brain barrier and inhibits CNS IFNa during encephalitis. Studies initiated in the previous granting period included the determination of effectiveness using a current combined antiretroviral therapy (cART) regimen in treating HIVE mice. These studies will also be extended by combining B18R with this cART regimen to determine if the combination is more efficacious than either alone. Importantly, these studies using both the B18R plus the cART regimen should more closely simulate human conditions, where cART reduces viral load but does not prevent HAND; therefore it is hypothesized that the two together will reduce viral load and ameliorate behavioral abnormalities in mice.. Moreover, proposed in vitro studies will extend previous in vitro results by examining the effects of IFNa on neurons to further elucidate the mechanisms of IFNa neurotoxicity. It is assumed that neurotoxicity stems from IFNa receptor (IFNaR) engagement, although previous studies mentioned above indicate that NMDA receptors also play a role. Therefore in vitro studies will determine whether IFNaR engagement correlates with downstream IFNa signaling and dendritic abnormalities. In addition, pathways involved in dendritic formation will be investigated through gene array analysis in neurons after IFNa exposure. Identification of pathways involved in the disruption of dendritic formation will contribute to understanding the basic mechanisms of memory formation and could lead to better treatments of cognitive dysfunction.

描述（由申请人提供）：